ArticleJournal of clinical microbiology2014
Real-time cellular analysis coupled with a specimen enrichment accurately detects and quantifies Clostridium difficile toxins in stool.
Article in Journal of clinical microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Advances in diagnostic assays forFrontiers in cellular and infection microbiology · 2024Review
- Rapid discrimination between clinicalFrontiers in microbiology · 2024Article
- Nanobodies against C. difficile TcdA and TcdB reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivo.PLoS pathogens · 2023Article
- Intestinal bile acids provide a surmountable barrier againstProceedings of the National Academy of Sciences of the United States of America · 2023Article
- Ultrasensitive and Quantitative Toxin Measurement Correlates With Baseline Severity, Severe Outcomes, and Recurrence Among Hospitalized Patients With Clostridioides difficile Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Genomic evolution and virulence association ofEmerging microbes & infections · 2021Article
- Faecal microbiota transplantation for Clostridioides difficile: mechanisms and pharmacology.Nature reviews. Gastroenterology & hepatology · 2021Review
- Application of xCELLigence real-time cell analysis to the microplate assay for pertussis toxin induced clustering in CHO cells.PloS one · 2021Article
- Binding and neutralization of C. difficile toxins A and B by purified clinoptilolite-tuff.PloS one · 2021Article
- Ultrasensitive Clostridioides difficile Toxin Testing for Higher Diagnostic Accuracy.Journal of clinical microbiology · 2020Review
- Real-time cell analysis system in cytotoxicity applications: Usefulness and comparison with tetrazolium salt assays.Toxicology reports · 2020Review
- High-Level Resistance of ToxigenicInfection and drug resistance · 2020Article
- Fecal calprotectin concentrations in cancer patients with Clostridium difficile infection.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2018Article
- Ultrasensitive Detection of Clostridioides difficile Toxins A and B by Use of Automated Single-Molecule Counting Technology.Journal of clinical microbiology · 2018Article
- Microbiota-accessible carbohydrates suppress Clostridium difficile infection in a murine model.Nature microbiology · 2018Article
- Identification and Characterization of Clostridium difficile Sequence Type 37 Genotype by Matrix-Assisted Laser Desorption IonizationJournal of clinical microbiology · 2018Article
- Simultaneous detection and characterization of toxigenic Clostridium difficile directly from clinical stool specimens.Frontiers of medicine · 2018Article
- Advances in the diagnosis and treatment of Clostridium difficile infections.Emerging microbes & infections · 2018Review
- Molecular Epidemiology of Clostridium difficile Infection in Hospitalized Patients in Eastern China.Journal of clinical microbiology · 2017Article
- Ultrasensitive Detection and Quantification of Toxins for Optimized Diagnosis of Clostridium difficile Infection.Journal of clinical microbiology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We describe here the use of an immunomagnetic separation enrichment process coupled with a modified real-time cellular analysis (RTCA) system (RTCA version 2) for the detection of C. difficile toxin (CDT) in stool. The limit of CDT detection by RTCA version 2 was 0.12 ng/ml. Among the consecutively collected 401 diarrheal stool specimens, 53 (13.2%) were toxin-producing C. difficile strains by quantitative toxigenic culture (qTC); bacterial loads ranged from 3.00 × 10(1) to 3.69 × 10(6) CFU/ml. The RTCA version 2 method detected CDT in 51 samples, resulting in a sensitivity of 96.2%, a specificity of 99.7%, and positive and negative predictive values of 98.1% and 99.4%, respectively. The positive step time ranged from 1.43 to 35.85 h, with <24 h for 80% of the samples. The CDT concentrations in stool samples determined by RTCA version 2 correlated with toxigenic C. difficile bacterial load (R(2) = 0.554, P = 0.00002) by qTC as well as the threshold cycle (R(2) = 0.343, P = 0.014) by real-time PCR. A statistically significant correlation between the CDT concentrations and the clinical severity of CDI was observed (P = 0.015). The sensitivity of the RTCA version 2 assay for the detection of functional toxins in stool specimens was significantly improved when the immunomagnetic separation enrichment process was incorporated. More than 80% positive results can be obtained within 24 h. The stool specimen CDT concentration derived using the RTCA version 2 assay correlates with clinical severity and may be used as a marker for monitoring the status of CDI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.